Study of BG-C137 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumors that have been confirmed by a biopsy or other lab test.
- You have already tried standard treatments for your cancer, and either they stopped working, caused side effects, or your doctor thinks another treatment isn't right for you.
- Your tumor has a specific marker called FGFR2b (either the protein itself or a gene change that makes more of it). You must agree to provide a tissue sample from a past biopsy or have a new one taken.
- You have at least one measurable tumor (as seen on scans) and your overall health is good (ECOG score 0 or 1), meaning you can do most daily activities without help.
- You do not have active eye problems like severe dry eyes, corneal damage, or a history of corneal transplant.
- You have not had certain other targeted or antibody drug conjugate treatments before, and you are not currently getting other cancer therapies.
- You do not have untreated brain metastases, spinal cord compression, or a history of lung inflammation (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.